Loading clinical trials...

AST-120 Used to Treat Mild Hepatic Encephalopathy | Clinical Trials | Clareo Health

COMPLETEDPhase 2NCT00867698

AST-120 Used to Treat Mild Hepatic Encephalopathy

The purpose of this study is to determine whether AST-120 is safe and effective in the treatment of mild hepatic encephalopathy.

Lead sponsor: Ocera Therapeutics•38 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment148

Start dateMar 2009

Last updatedJun 18, 2014

Condition

Mild Hepatic Encephalopathy

Locations shown

University of Alabama at Birmingham

Birmingham, Alabama

Mayo Clinic Arizona

Phoenix, Arizona

UCSF - Fresno Community Regional Medical Center

Fresno, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 18, 2014Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions